A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma

Clinical Rheumatology

Volumn 30, Issue 2, 2011, Pages 223-229

  Domiciano, Diogo S ^a   Bonfá, Eloisa ^a   Borges, Claudia T L ^a   Kairalla, Ronaldo A ^a   Capelozzi, Vera L ^a   Parra, Edwin ^a   Christmann, Romy Beatriz ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Corticosteroid; Cyclophosphamide; Interstitial lung disease; Systemic sclerosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; PREDNISONE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LYMPHOCYTOPENIA; MODIFIED RODNAN SKIN SCORE; MONOTHERAPY; MORTALITY; NAUSEA; NONSPECIFIC INTERSTITIAL PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA; SCORING SYSTEM; SINUSITIS; SKIN INFECTION; SYSTEMIC SCLEROSIS; URINARY TRACT INFECTION; VOMITING;

ADULT; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 79954435537     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1493-4     Document Type: Article

References (30)

1. Simeon CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42:71-75. (Pubitemid 36131570)
2. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ et al (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118:2-10. (Pubitemid 40082450)
3. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA et al (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22:1876-1883.
4. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM (1997) Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40:743-51.
5. Owens GR, Paradis IL, Gryzan K, Medsger TA Jr, Follansbee WP, Klein HA et al (1986) Roles of inflammation in the lung disease of systemic sclerosis: comparison with idiopathic pulmonary fibrosis. J Lab Clin Med 107:253-260. (Pubitemid 16024764)
6. Fujita J, Yoshinouchi T, Ohtsuki Y, Tokuda M, Yang Y, Yamadori I et al (2001) Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 60:281-283. (Pubitemid 32260614)
7. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P et al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581-1586. (Pubitemid 34693935)
8. Kim DS, Yoo B, Lee JS, Kim EK, Lim CM, Lee SD et al (2002) The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 19:121-127. (Pubitemid 34685911)
9. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277-304.
10. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst D, for the Scleroderma Lung Study Research Group et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655-2666.
11. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL et al (2006) A Multicenter, prospective, randomized, double-blind, placebo-controlles trial os corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3692-3970.
12. Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG et al (2002) Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 298-304. (Pubitemid 34118777)
13. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conforti ML et al (2002) Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 29:731-736. (Pubitemid 34303867)
14. Griffithis B, Miles S, Mos H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using oulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371-2378. (Pubitemid 35266028)
15. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooniz EA, Grossz BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275-283. (Pubitemid 34162828)
16. de Souza RB, Borges CT, Capelozzi VL, Parra ER, Jatene FB, Kavakama J et al (2008) Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 18:1-9.
17. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-90.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205. (Pubitemid 18073738)
19. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA et al (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 25:84-88. (Pubitemid 28060123)
20. de Carvalho ME, Kairalla RA, Capelozzi VL, Deheinzelin D, do Nascimento Saldiva PH, de Carvalho CR (2002) Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia. Pathol Res Pract 198:577-583. (Pubitemid 35244054)
21. Cotes JE, Dabbs JM, Elwood PC, Hall AM, McDonald A, Saunders MJ (1972) Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusion capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci 42:325-335.
22. Antoniou KM, Wells AU (2008) Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 20:686-691.
23. Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk AM, Haznedaroglu IC et al (2003) Effects os oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early systemic sclerosis. Arthritis Rheum 48:2256-2261. (Pubitemid 36959207)
24. SimeOn-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva- O'Callaghan A, Solans-Laque R, Palliza E, Munoz X, Vilardell- Tarres M (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long-term study. Open Respir Med J 2:39-45.
25. Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi M et al (2007) Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase. Clin Exp Rheumatol 25:293-296. (Pubitemid 46851434)
26. Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L et al (2007) Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 26:168-172. (Pubitemid 46020237)
27. Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG (2007) Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease. Clin Exp Rheumatol 25:734-739. (Pubitemid 350284846)
28. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA et al (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 1932:947-954. (Pubitemid 30397594)
29. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, for the Scleroderma Lung Study Research Group et al (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 176:1026-1034. (Pubitemid 350127847)
30. Valentini G, Paone C, Montagna GL, Menegozzo M, Colutta E, Ruocco L (2006) Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scan J Rheumatol 35:35-38. (Pubitemid 43247252)